生物活性

• 描述Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently. Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group^[3]. Octreotide can decrease the rate of postoperative complication after pancreatic resection by diminishing exocrine function of the pancreas. Prophylactic octreotide is not effective to inhibit the exocrine secretion of the remnant pancreas and does not decrease the incidence of pancreatic fistula after pancreaticoduodenectomy^[4]. The prophylactic use of LAO (long-acting octreotide acetate) did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL(quality of life)^[5]. Octreotide LAR (octreotide acetate) 20 mg shows significant efficacy in terms of objective response rate (PR + SD), biochemical and symptomatic control in patients with metastatic NETs (neuroendocrine tumors) of the GEP system pretreated and progressing on slow release lanreotide^[6].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00274170	Migraine Headache	Phase 1 Phase 2	Unknown	-	United States, Texas ... more >> CR Darnall Army Medical Center Recruiting Ft. Hood, Texas, United States, 76544 Collapse <<
  NCT00616551	Acromegaly	Phase 3	Completed	-	Belarus ... more >> Republican Centre for Medical Rehabilitation and Water-therapy Minsk, Belarus Hungary Semmelweis Egyetem Általános Orvostudományi Budapest, Hungary Romania Institute of Endocrinology "C. I. Parhon" Bucharest Bucharest, Romania Serbia Institute of Endocrinology, University Clinical Center Belgrade, Serbia Slovakia Fakultná Nemocnica s Poliklinkou Bratislava Bratislava, Slovakia Ukraine V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine Kiev, Ukraine Collapse <<
  NCT00003057	Colorectal Cancer ... more >> Diarrhea Collapse <<	Phase 3	Completed	-	-

• 更多
• 参考文献

• [1] Wang M, Shan F, et al. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56.

  [2] Kim S, Hosoya K, et al. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12.

  [3] Wang M, Shan F, Zou Y, Sun X, Zhang ZR, Fu Y, Gong T. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56

  [4] You DD, Paik KY, Park IY, Yoo YK. Randomized controlled study of the effect of octreotide on pancreatic exocrine secretion and pancreatic fistula after pancreatoduodenectomy. Asian J Surg. 2019 Feb;42(2):458-463

  [5] Zachariah B, Gwede CK, James J, Ajani J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. J Natl Cancer Inst. 2010 Apr 21;102(8):547-56

  [6] Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000 Sep;11(9):1127-30

• 更多

• Collapse